UroGen Pharma (URGN) announced that Chris Degnan has been appointed CFO. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. Degnan joins UroGen with extensive experience as a publicly traded biotech CFO, most recently at Galera Therapeutics (GRTX).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: